HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

If Successful, HRA Pharma Acquisition Will Complete Perrigo’s Pivot Towards Self-Care

Executive Summary

If its acquisition of France's HRA Pharma completes, Perrigo will have “enough growth in our back pocket for the next three to five years without making any further acquisitions,” says the firm’s UK & Ireland chief, Neil Lister, in an exclusive interview with HBW Insight. 

You may also be interested in...



HRA Proposes OTC Norgestrel Birth Control

HRA has worked with Ibis Reproductive Health, which supports the Free the Pill advocacy group, to conduct research for a norgestrel switch NDA.

HBW Insight’s Key Takeaways From 2021: #1 Join The Self-Care Movement

The first year of the pandemic saw a move among consumers towards prevention and wellness under the banner of "self-care". In 2021, the "self-care movement" really started to gain momentum as these new healthcare habits endured, and companies responded with more wellness options, in some cases even pivoting towards becoming pure self-care players. 

Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19

Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel